Status:

COMPLETED

Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study

Lead Sponsor:

National Institute of Cardiology, Warsaw, Poland

Collaborating Sponsors:

Solvay Pharmaceuticals

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

30-80 years

Phase:

PHASE2

PHASE3

Brief Summary

Background: Influenza vaccination is recommended in patients (pts) with cardiovascular disease, however there is a shortage of clinical studies proving its protective effect on clinical course of coro...

Detailed Description

A possible relation between influenza and higher mortality from cardiovascular problems was first noticed in early nineteen hundreds, after epidemics in Europe and United States were discovered (1). I...

Eligibility Criteria

Inclusion

  • Patients, aged 30-80 years, with CAD confirmed by coronarography with at least 50% stenosis of one large epicardial coronary artery.

Exclusion

  • planned cardiovascular surgery within 6 months, congestive heart failure NYHA III/IV, evolving renal failure, neoplastic disease, psycho-organic disorder or any factor impeding follow-up, contraindication to vaccination.

Key Trial Info

Start Date :

October 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2005

Estimated Enrollment :

658 Patients enrolled

Trial Details

Trial ID

NCT00371098

Start Date

October 1 2004

End Date

December 1 2005

Last Update

October 23 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

1st Dept. of Coronary Artery Disease, Institute of Cardiology

Warsaw, Poland, 04-628

Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD Study | DecenTrialz